Search PubMed⌕ Search

Biomedical subjects

S A Plotkin

Publications and source records attributed to S A Plotkin.

At least 307 records · Page 17Linked to original sources
PubMed1967

Warts.

Explore the source record for details and available documents.

Animals↗
PubMedDate not supplied

The status of cytomegalovirus vaccine.

Live attenuated Towne strain cytomegalovirus vaccine was evaluated in healthy volunteers and renal transplant recipients. Immunization induced humoral and cell-mediated immune responses in both groups, although responses were of a higher magnitude in healthy volunteers. Immunization of candidates for renal transplantation with Towne vaccine significantly reduced the incidence of moderately severe and severe cytomegalovirus disease in high-risk recipients after transplantation. Reactivation of vaccine-strain virus was not detected. While the use of live attenuated Towne strain vaccine for prevention of primary cytomegalovirus infections in solid-organ transplant recipients and pregnant women deserves further consideration, efforts are also under way to develop a subunit cytomegalovirus vaccine.

Antibodies, Viral↗
PubMedDate not supplied

Vaccines for the prevention of human cytomegalovirus infection.

The status of vaccination against cytomegalovirus (CMV) at the end of 1988 was as follows: (1) The Towne live attenuated vaccine produces humoral and cellular immune responses without viral excretion or demonstrated latency. (2) The Towne vaccine partially protects seronegative renal transplant recipients from severe CMV disease but does not prevent them from getting infected. (3) In healthy subjects the live vaccine is also protective, but protection is related to challenge dose. Vaccine-derived immunity is equivalent to natural immunity for prevention of disease but at higher challenge doses is less protective for prevention of infection. (4) The viral envelope contains proteins that can stimulate humoral and cellular immune responses, although it is not yet clear whether the responses are as protective as those following infection. (5) One glycoprotein of the envelope, the 55-58K protein, can stimulate the same responses. If large amounts of this protein can be produced by molecular biologic techniques, this protein might be used as a subunit vaccine. (6) Target groups for vaccination would include seronegative healthy women and seronegative or seropositive recipients of solid organ transplants.

Antibodies, Viral↗